MiMedx Group, Inc (NASDAQ:MDXG) Given Consensus Recommendation of “Moderate Buy” by Brokerages

MiMedx Group, Inc (NASDAQ:MDXG) has been given an average rating of “Moderate Buy” by the seven brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $8.50.

A number of equities research analysts have commented on MDXG shares. Citizens Jmp cut their target price on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a research report on Thursday, April 30th. Weiss Ratings reissued a “sell (d)” rating on shares of MiMedx Group in a report on Thursday. Finally, Wall Street Zen downgraded MiMedx Group from a “hold” rating to a “sell” rating in a research note on Saturday, August 1st.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. purchased a new stake in shares of MiMedx Group in the 2nd quarter worth $46,795,000. Paradigm Capital Management Inc. NY purchased a new position in MiMedx Group during the second quarter valued at $15,681,000. Nantahala Capital Management LLC bought a new stake in MiMedx Group during the third quarter valued at about $10,237,000. Marshall Wace LLP increased its position in MiMedx Group by 864.9% in the fourth quarter. Marshall Wace LLP now owns 1,381,288 shares of the company’s stock worth $9,351,000 after buying an additional 1,238,132 shares in the last quarter. Finally, Hillsdale Investment Management Inc. purchased a new stake in MiMedx Group in the fourth quarter worth about $7,134,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Stock Performance

NASDAQ MDXG opened at $4.27 on Monday. MiMedx Group has a 12 month low of $3.03 and a 12 month high of $7.97. The company has a current ratio of 5.33, a quick ratio of 4.79 and a debt-to-equity ratio of 0.07. The stock’s fifty day moving average price is $4.04 and its 200-day moving average price is $4.14. The stock has a market cap of $622.40 million, a P/E ratio of 106.78 and a beta of 1.45.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings results on Wednesday, July 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). The firm had revenue of $64.36 million during the quarter, compared to analyst estimates of $63.46 million. MiMedx Group had a return on equity of 12.09% and a net margin of 1.76%. As a group, equities analysts forecast that MiMedx Group will post -0.1 EPS for the current fiscal year.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.